Buparvaquone

Buparvaquone is a hydroxynaphthoquinone antiprotozoal agent used in the treatment of theileriosis, a disease caused by Theileria parasites. It is particularly effective against Theileria parva and Theileria annulata, which are responsible for East Coast fever and Tropical theileriosis, respectively.

Mechanism of Action

Buparvaquone works by inhibiting the mitochondrial electron transport chain in Theileria parasites. This disruption leads to a decrease in adenosine triphosphate (ATP) production, which is essential for the survival and replication of the parasites.

Pharmacokinetics

Buparvaquone is administered via intramuscular injection. It has a long half-life, which allows for sustained therapeutic levels in the bloodstream. The drug is metabolized in the liver and excreted primarily through bile.

Clinical Use

Buparvaquone is used in veterinary medicine to treat cattle infected with Theileria parva and Theileria annulata. It is often administered as part of a comprehensive treatment plan that includes supportive care and management of tick populations, which are vectors for Theileria parasites.

Side Effects

Common side effects of buparvaquone include local reactions at the injection site, such as swelling and pain. In rare cases, systemic reactions such as fever and lethargy may occur.

Resistance

There have been reports of resistance to buparvaquone in some Theileria populations. This resistance is thought to be due to mutations in the parasite's mitochondrial DNA, which reduce the drug's efficacy.

Research

Ongoing research is focused on understanding the mechanisms of resistance to buparvaquone and developing new antiprotozoal agents to combat resistant strains of Theileria.

See Also

• Theileriosis
• Theileria
• East Coast fever
• Tropical theileriosis
• Antiprotozoal agent